CM: Blood donation awareness needs to be enhanced
Shahelmey performing the gimmick launching of the state-level 2025 Nurses' Day celebrations and blood donation event held at Queen Elizabeth II Hospital.
KOTA KINABALU (May 13): Chief Minister, Datuk Seri Panglima Haji Hajiji Haji Noor wants more programmes to be implemented to raise awareness on the importance of donating blood.
'I have been informed that the daily blood requirement for Sabah is 300 units and each year, we need about 110,000 to 120,000 units to meet patients' needs. However, to date, only 75,000 units are collected each year,' he said at the state-level 2025 Nurses' Day celebrations and blood donation event held at Queen Elizabeth II Hospital here on Tuesday.
His speech was delivered by Deputy Chief Minister III/Minister of Works Datuk Ir Shahelmey Yahya.
Hajiji said collaboration between the Ministry of Health and the public sector can raise awareness on blood donation and to attract the public to become regular donors.
'Indeed, voluntary blood donation helps save patients' lives,' he said.
He said since the quality of the healthcare system heavily relies on the quality of the nursing workforce, investment in training, welfare and career development for nurses is crucial to ensure the sustainability of the country's healthcare system.
'In this regard, the State Government always appreciates and supports nurses serving in Sabah who sacrifice their time and energy for the health of the people. I hope all nurses will continue to strive to improve the quality of healthcare services, particularly in this state,' he said.
The Chief Minister paid tribute to nurses, whom he said are the backbone of the nation's healthcare system.
'The Nurses' Day celebrations is not just a symbolic event but a significant recognition of the group that serves as the backbone of the nation's healthcare system – our nurses.
'In line with this year's theme, 'Our Nurses, Our Future: Caring for Nurses Strengthens the Economy', the role of nurses extends beyond just being 'patient caregivers' in hospitals – they are also catalysts for community well-being, health educators, and frontline workers in managing health crises,' he said.
The Chief Minister recalled the extraordinary role of nurses during the Covid-19 pandemic a few years ago, not only in terms of treatment and monitoring but also in providing emotional and moral support to patients and their families.
'Some had to be separated from their families, spouses, and children in order to fulfill their responsibilities at that time.
'Indeed, they are unsung heroes who remain strong, resilient and steadfast working under various challenging situations, whether in wards, emergency units, rural health clinics or disaster areas,' he said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Star
4 hours ago
- The Star
Middle-aged man in Cambodia dies of H5N1 bird flu
PHNOM PENH (Bernama-Xinhua): A 52-year-old man from southeastern Cambodia's Svay Rieng province had died of H5N1 human avian influenza, becoming the fifth human death from the virus so far this year. "A laboratory result from the National Institute of Public Health showed on June 20 that the man was positive for H5N1 virus," the Ministry of Health said in a press statement on Saturday. Health authorities are looking into the source of the infection and are examining any suspected cases or people who have been in contact with the victim in order to prevent an outbreak in the community, it added. Tamiflu (oseltamivir), an antiviral drug to prevent the bird flu from spreading, was also given out to people who had direct contact with the patient, the statement said. The South-East Asian country recorded a total of six human cases of H5N1 so far this year, with five deaths. - Bernama-Xinhua
Malaysian Reserve
a day ago
- Malaysian Reserve
Molecular Point-of-Care (mPOC) Market Reaches $1.8 Billion: Kalorama Report Spotlights Rapid PCR Innovation and Expanding Frontiers in STI and HAI Testing
ARLINGTON, Va., June 20, 2025 /PRNewswire/ — Kalorama Information, a leading authority in in vitro diagnostics (IVD) market research, has released Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024–2029, estimating the global mPOC market at $1.8 billion in 2024. The report offers a comprehensive forecast through 2029, highlighting transformative opportunities in respiratory, sexually transmitted, and hospital-acquired infection diagnostics at or near the point of care. 'While the molecular point-of-care market saw unprecedented acceleration during the COVID-19 pandemic, Kalorama's latest analysis reveals it now stands on a firmer foundation with renewed growth expected,' said Justin Saeks, senior market analyst and report author. 'We anticipate an almost double-digit compound annual growth rate for the 'true' mPOC segment as demand spreads beyond COVID to broader respiratory panels, STIs, HAIs, and tropical diseases.' Key Findings from the Report: Respiratory testing dominates the market, with COVID-19, flu, strep, and RSV continuing to drive system adoption, particularly for combination tests. Growth expected in HAIs and STIs, although these will evolve more slowly due to testing infrastructure and workflow differences across care settings. 'True' mPOC segment revenues, which had recently declined, are projected to achieve a substantial CAGR from 2024 to 2029. Kalorama differentiates between 'true' mPOC platforms and near-patient systems, offering detailed segmentation by company, region, and disease target. Abbott and Cepheid lead their respective segments. True mPOC Systems: Compact, fast, CLIA-waived (or with waiver potential), and operable by non-lab personnel. Key players include Abbott (market leader), Roche, Cepheid, QuidelOrtho, BioFire, and Sekisui. Near-Patient Molecular Systems: Encompasses larger non-POC systems and smaller platforms with POC or near-POC potential. BioFire and Cepheid are major competitors, with Cepheid leading this segment. Why It Matters Now The report's release is timely as healthcare providers seek diagnostic solutions that balance speed, accuracy, and accessibility across both developed and resource-limited settings. mPOC systems bring the power of molecular testing to emergency departments, outpatient clinics, nursing homes, mobile labs, and even homes—enabling timely treatment decisions and improving care outcomes. 'POC molecular diagnostics represent one of the most important intersections between innovation and access in global health,' said Alisa Alvich, Marketing Director at Science and Medicine Group, Kalorama Information's parent company. 'Kalorama's analysis shows where this market is headed and what players must consider to stay competitive.' Audience Impact This research is essential for: Product Managers and R&D leaders developing decentralized molecular platforms. Corporate strategy teams evaluating new market opportunities or CLIA-waived innovations. Investors and M&A professionals scouting high-growth segments or acquisition targets. Clinical lab and procurement teams optimizing test menus for decentralized care delivery. With deep dives into market sizing, disease applications, regional dynamics, and competitive intelligence, Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024–2029 equips life sciences professionals with the insights needed to navigate a rapidly evolving diagnostics frontier. Get the Report Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024–2029 is now available for purchase at: For purchasing inquiries or to schedule a custom consultation, contact:Sheri Davie – Sales Director, Kalorama About Kalorama Information Kalorama Information, part of Science and Medicine Group Inc., is a trusted publisher of market research exclusively focused on the healthcare industry. For over 25 years, Kalorama has delivered accurate, timely, and strategic intelligence to leaders in biotechnology, clinical diagnostics, in vitro diagnostics (IVD), pharmaceuticals, medical devices, and broader healthcare sectors. Originally launched in 1998, Kalorama Information quickly established itself as a premier source of insight into U.S. and global medical markets. Today, Kalorama remains a leading authority on healthcare market dynamics, with a particular emphasis on IVD. Kalorama is best known for its flagship title, The Worldwide Market for In Vitro Diagnostic Tests, an internationally recognized benchmark in the diagnostics field. Other reports published throughout the year cover these and other healthcare topics in greater detail. Our innovative approach to research, combined with deep industry expertise, has made Kalorama a go-to resource for top healthcare companies, strategic planners, investors, and media seeking authoritative market data and trends. With a singular focus on healthcare, Kalorama continues to shape informed decision-making across the industry through comprehensive, evidence-based analysis. Kalorama also works in coordination with other Science and Medicine Group brands, including BioInformatics, which focuses on life science markets and marketing, SDi, the leading source of information on the laboratory life science and analytical instrumentation industry and publisher of IBO, its twice-monthly newsletter, and IMV, which publishes reports and data on the medical imaging and clinical markets. For more information about Kalorama Information and other services offered by Science and Medicine Group, please visit our website.
Rakyat Post
a day ago
- Rakyat Post
Malaysia Records First COVID-19 Death In 2025
Subscribe to our FREE Malaysia has recorded its first COVID-19-related death of 2025, according to a statement released by the Ministry of Health (MoH) on 19 June. The fatality occurred during Epidemiological Week 24 (8–15 June). The individual, who had serious pre-existing health conditions such as heart disease and diabetes, had not received the second booster dose of the COVID-19 vaccine. MoH noted that this was the first COVID-19 death since 26 May 2024, and a significant drop compared to the 57 COVID-related deaths reported in 2024. COVID-19 Cases on the Rise, But Situation Under Control As of Week 24, Malaysia has reported 21,738 cumulative COVID-19 cases in 2025, with the weekly average hovering around 900 cases. However, MoH did flag a 68% week-on-week spike, with 3,379 cases reported in Week 24 compared to 2,011 the previous week. Despite the increase, the ministry assured that the national COVID-19 situation remains stable and below the national alert threshold. In terms of severe cases, six patients were admitted to the ICU, all with underlying health issues. All have since been discharged from intensive care; four have returned home, while two remain in regular hospital wards for follow-up treatment. New Variant on the Radar: NB.1.8.1 or 'Nimbus' The World Health Organisation (WHO) is closely monitoring the spread of NB.1.8.1, a Photo: Freepik WHO has classified Nimbus as a Variant Under Monitoring (VUM) due to its rapid transmission and potential health risks. Nimbus spreads faster than previous variants. Common symptoms include: razor-blade-like sore throat, fatigue, mild cough, fever, muscle aches and nasal congestion. What You Can Do Health experts continue to urge the public to take precautions, especially as new variants emerge. Wear a high-quality mask in crowded indoor spaces, improve indoor ventilation: open windows, use fans or air purifiers, get tested if you're feeling unwell or exposed to COVID-19, and stay home when sick to reduce the risk of transmission. Photo: Malay Mail While Malaysia's current COVID-19 situation remains under control, this latest death and the emergence of new variants serve as reminders that vigilance and public health measures remain crucial. Share your thoughts with us via TRP's . Get more stories like this to your inbox by signing up for our newsletter.
